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Abstract
Background: In the present study, we investigated whether thymosin β (Tβ) in saliva and in minor salivary glands
is differentially expressed in patients with primary Sjögren’s syndrome (pSS) and patients with autoimmune diseases
(systemic sclerosis [SSc], systemic lupus erythematosus [SLE], and rheumatoid arthritis [RA], with and without sicca
syndrome [ss]).
Methods: Saliva specimens of nine patients with pSS, seven with ss/SSc, seven with ss/SLE, seven with ss/RA, seven
with SSc, seven with SLE, and seven with RA, as well as ten healthy subjects, were analyzed using a high-performance
liquid chromatograph coupled with a mass spectrometer equipped with an electrospray ionization source to investigate
the presence and levels of Tβ4, Tβ4 sulfoxide, and Tβ10. Immunostaining for Tβ4 and Tβ10 was performed on minor
salivary glands of patients with pSS and ss.
Results: Tβ4 levels were statistically higher in patients with pSS with respect to the other subgroups. Tβ10 was
detectable in 66.7 % of patients with pSS and in 42.8 % of those with ss/SSc, while Tβ4 sulfoxide was detectable
in 44.4 % of patients with pSS and in 42.9 % of those with ss/SSc. Tβ10 and Tβ4 sulfoxide were not detectable in
patients without associated ss and in healthy control subjects. Regarding thymosin immunostaining, all patients
had immunoreactivity for Tβ10, and a comparable distribution pattern in the four different subgroups of patients
was observed. Tβ4 immunoreactivity was present in patients with ss/SSc and those with ss/SLE, while it was
completely absent in patients with pSS and those with ss/RA.
Conclusions: Our data show that higher salivary Tβ expression characterizes patients with pSS, while Tβ4 sulfoxide and
Tβ10 salivary expression was selectively present in patients with sicca symptoms. Moreover, at the immunohistochemical
level in patients with pSS, minor salivary glands showed a peculiar pattern characterized by immunostaining for Tβ10 in
acinar cells in the absence of any reactivity for Tβ4. These findings, taken together, suggest a different role for Tβ4 and
Tβ10 in patients with pSS who have ss and other autoimmune disease.




1Division of Rheumatology, Fondazione Policlinico Universitario Agostino
Gemelli, Rome, Italy
5Institute of Rheumatology and Affine Sciences, Universita’ Cattolica del
Sacro Cuore, Presidio Columbus, Via Giuseppe Moscati, 31, 00168 Rome, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bosello et al. Arthritis Research & Therapy  (2016) 18:229 
DOI 10.1186/s13075-016-1134-7
Background
Primary Sjögren’s syndrome (pSS) is a chronic auto-
immune disease characterized by lymphocytic infiltration
of the exocrine glands, including salivary and lachrymal
glands, leading to qualitatively altered and diminished or
absent glandular secretion. pSS is also characterized by
marked B-lymphocyte hyperreactivity supported by
hypergammaglobulinemia associated with the increase
of a variety of serum autoantibodies [1]. The character-
istic involvement of salivary and lachrymal glands, clin-
ically evidenced by dry mouth (xerostomia) and/or dry
eyes (xerophthalmia), makes pSS an interesting applica-
tion field for salivary proteomic analysis. Saliva and tears
are easy and noninvasive biological fluids to collect and
can mirror local and systemic pathological changes of the
disease [2–4]. In previous studies on the salivary proteome
in patients with pSS, researchers identified a number of
proteins as possible pSS biomarkers. Some of these bio-
markers showed significantly different levels from those of
healthy subjects, whereas other biomarkers were detected
exclusively in the saliva of patients with pSS [3–6]. In
general, proteins of acinar origin were reduced in patients
with pSS, whereas acute inflammatory phase proteins
were increased in subjects with pSS, compared with those
of healthy subjects.
Recently, β-thymosins (Tβs), a versatile family of small
peptides with interesting intra- and extracellular activities
that include cardiac protection, angiogenesis, stimulation of
wound healing, and hair growth [7–16], was identified in
human saliva and in tears [17, 18]. Tβs play pivotal roles in
the cell cytoskeletal system, acting as G-actin-sequestering
molecules, suggesting that their release by damaged cells
might play a role in tissue repair, such as in damaged
cornea [19]. In particular, Tβ4, the most abundant Tβ in
human tissues [7, 8], plays an important role in suppress-
ing the production of interleukin-8 following stimulation
by tumor necrosis factor-α, acting as an antimicrobial,
anti-inflammatory, and antiapoptotic factor on gingival fi-
broblasts [20]. Moreover, our group recently reported that
Tβs are probably involved in the development of the oral
cavity and its annexes [21]. Another member of the Tβ
family, Tβ10, is usually detectable at concentrations about
five- to tenfold lower than Tβ4 in human tissues, but it
has been reported to be overexpressed in human carcino-
genesis [22] and in fetal tissues, including the developing
human brain [23]. Involvement of Tβ10 in the develop-
ment of the oral cavity, and in particular tooth germ
development and tooth root formation, was reported
recently in a mice study [24]. In addition, our group re-
ported strong expression of Tβ10 in the human salivary
glands during development [21]. Tβ4 sulfoxide was re-
ported to have anti-inflammatory properties [25], being
overexpressed in the presence of oxidative stress, due
to its potential scavenger properties [26].
Because, to the best of our knowledge, no data had
previously been reported on the presence of Tβ4, Tβ4
sulfoxide, and Tβ10 in human saliva of patients with
Sjögren’s syndrome (SS), the aim of this study was to inves-
tigate the presence and levels of salivary Tβs and the im-
munoreactivity of these peptides in minor salivary glands
in a cohort of patients with SS and in patients with other
autoimmune diseases, with and without sicca syndrome
(ss), to better understand the possible role of these peptides
in patients with pSS as well as patients with ss and other
autoimmune diseases.
Methods
Patients and control subjects
All female patients were enrolled at the rheumatology
clinic at the Catholic University of Rome, and the study
was approved by the Catholic University Ethics Commit-
tee in Rome. After we obtained signed informed consent,
we collected saliva specimens from nine patients with pSS
according to previous and revised criteria for the disease
[27, 28]. Patients with pSS had a mean age of 63.0 ± 11.2
years and a mean disease duration of 12.0 ± 7.1 years
(Table 1).
As control subjects, we considered three age-matched
groups:
1. Ten healthy subjects who had no signs or symptoms
of ss and who were antinuclear autoantibody-negative,
anti-extractable nuclear antigen autoantibody-negative,
and rheumatoid factor autoantibody-negative
2. Twenty-one patients with ss associated with
systemic sclerosis (SSc) (seven patients), with
systemic lupus erythematosus (SLE) (seven patients),
and with rheumatoid arthritis (RA) (seven patients);
all of these patients complained of xerostomia and
xerophthalmia, had a Schirmer test result <5 mm in
5 minutes, and had unstimulated whole saliva flow
<1.5 ml in 15 minutes [27], and none of them had
anti-Ro/SSA or anti-La/SSB autoantibodies and
lymphocytic infiltration of the salivary glands
3. Seven patients with SSc, seven with SLE, and seven
with RA without symptoms or signs of ss
All patients were diagnosed according to the revised
international classification criteria for SSc, SLE, and RA
[29–31]. The disease durations were comparable in the
different patient study groups (Table 1).
In patients with pSS and with ss associated with SSc,
SLE, or RA, saliva specimens were also collected after 30
minutes, 60 minutes, and 24 h from 5-mg pilocarpine in-
take. Patients with pSS and SLE were receiving antimalar-
ial agents and a stable dose of prednisone <7.5 mg/day.
Patients with RA were treated with methotrexate 10–15
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mg/week. Patients with SSc were treated with iloprost,
calcium channel blockers, and acetylsalicylic acid.
Collection and preparation of saliva samples
Whole saliva was collected with a very soft plastic aspir-
ator between 2:00 PM and 4:00 PM to reduce variations
in concentrations associated with circadian rhythms of
secretion. Samples were collected at least 30 minutes
after any food or beverage had been consumed and teeth
had been cleaned. A total of 0.5 ml of saliva was collected
from each subject. Immediately after collection, samples
were placed in an ice bath, and 0.5 ml of an acidic solution
(0.2 % trifluoroacetic acid [TFA]) was added at a 1:1 ratio
(vol/vol). The solution was then centrifuged at 8000 × g
for 5 minutes at 4 °C. The supernatant was removed, and
the precipitate was discarded. The supernatant was imme-
diately analyzed by high-performance liquid chromatog-
raphy (HPLC) in conjunction with mass spectrometry
(MS) using a spectrometer equipped with an electrospray
ionization (ESI) source. HPLC-ESI-MS was performed
within 30 minutes of collection of the saliva sample.
HPLC-ESI-MS analysis of salivary proteins
The HPLC-ESI-MS apparatus used was a Surveyor HPLC
instrument (Thermo Fisher Scientific, Waltham, MA,
USA) connected by a T splitter to a photodiode array de-
tector and an LCQ Deca XP Plus mass spectrometer
(Thermo Fisher Scientific). The chromatography column
was a Vydac C8 column (Thermo Fisher Scientific) with a
5-μm particle diameter (column dimensions of 150 mm
in length × 2.1-mm inner dimension). The following so-
lutions were used for reversed-phase chromatography:
Eluent A consisted of 0.056 % (vol/vol) aqueous TFA,
and eluent B consisted of 0.050 % (vol/vol) TFA in
acetonitrile/water 80/20 (vol/vol). The gradient applied
was linear, from 0 % to 55 % of eluent B over 40 minutes,
at a flow rate of 0.30 ml/minute. The T splitter addressed
a flow rate of approximately 0.20 ml/minute toward the
diode array detector and a flow rate of about 0.10 ml/
minute toward the ESI source. The diode array detector
was set at two wavelengths: 214 nm and 276 nm. Mass
spectra were collected every 3 milliseconds in the positive
ion mode. The MS spray voltage was 4.50 kV, and the ca-
pillary temperature was 250 °C. All common chemicals
and reagents for the HPLC-MS analysis were of analyt-
ical grade and were purchased from Merck (Darmstadt,
Germany) and Baker (Mallinckrodt Baker B.V., Deventer,
the Netherlands). Deconvolution of the average ESI mass
spectra was automatically performed by using MagTran
1.0 software (Amgen, Thousand Oaks, CA, USA) [32].
Experimental mass values obtained from the analysis
were compared with theoretical values available from the
Swiss-Prot [33] and EMBL [34] databases. The relative
abundance of the different salivary Tβs was determined by
using the extracted-ion current (XIC) strategy. The XIC
procedure for each protein was based on the extraction
from the total ion current profile of three mass-to-charge
(m/z) values selected for each protein among the most
relevant, provided that these did not overlap with the m/z
values of nearly eluting proteins. Taking into account that
constant analytical conditions were used for each sample,
the numerical value corresponding to the integrated XIC
peak area was used for the estimations of the relative
abundance of peptides/proteins and for the statistical
analysis. The calculated areas are all referred to a saliva
volume of 17 μl. Standards of Tβ4 and Tβ10 were pur-
chased from Bachem (Bubendorf, Switzerland), and the
standard of Tβ4 sulfoxide was obtained, as previously
described, by oxidation of Tβ4 [17].
Immunohistochemical analyses
Samples of minor salivary glands were obtained through
an incisional biopsy taken (after inducing local anesthesia)
at the endobuccal border of the lower lip from six female
Table 1 Demographic and clinical characteristics of the patients and healthy control subjects enrolled in the study
pSS (n = 9) ss/SSc (n = 7) ss/SLE (n = 7) ss/RA (n = 7) SSc (n = 7) SLE (n = 7) RA (n = 7) HC (n = 10)
Age, years, mean ± SD 55.8 ± 13 63 ± 11 51 ± 16 61 ± 8 60.2 ± 7 48. ± 10 64.1. ± 9 56.6 ± 12.5
Disease duration, years, mean ± SD 7.9 ± 4.2 12 ± 7 12 ± 9 10 ± 7 10.4 ± 8 11 ± 8 9.4 ± 8 N/A
Anti-Ro/SSA- and/or anti-La/SSB-positive, n 9 0 0 0 0 0 0 0
ANA-positive, n 6 7 7 1 7 7 2 0
RF-positive, n 5 0 0 6 0 0 4 0
Focus score ≥1, n 6 0 0 0 N/A N/A N/A 0
UWS <1.5 ml/15 minutes, n 9 7 7 7 0 0 0 0
Schirmer test result <5 mm/5 minutes, n 9 7 7 7 0 0 0 0
Xerostomia, n 9 7 7 7 0 0 0 0
Xerophthalmia, n 9 7 7 7 0 0 0 0
Abbreviation: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc Systemic sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, HC Healthy
control subjects, UWS Unstimulated whole saliva, ANA Antinuclear antibodies, RF Rheumatoid factor, N/A Not applicable
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patients affected by SS, three with ss/SSc, three with
ss/SLE, and three with ss/RA, as well as from three
healthy control subjects. In patients with SS, minor
salivary gland samples had an average focus score >1
according to the Chisholm-Mason scoring system. The
focus score was calculated as the number of lympho-
cytic foci multiplied by 4-mm2 surface in at least four
informative lobules, and a focus was defined as a clus-
ter of at least 50 lymphocytes [35].
All tissue samples were fixed in 10 % formalin, routinely
processed, and embedded in paraffin. Immunohistochem-
istry was performed on 4-μm-thick sections using a la-
beled streptavidin-biotin complex system (LSAB2; Dako,
Glostrup, Denmark) in an autostainer (Dako Cytomation,
Carpinteria, CA, USA). Briefly, paraffin sections were
deparaffinized and rehydrated, and endogenous peroxid-
ase activity was quenched by 0.3 % hydrogen peroxide in
methanol (30 minutes). Heat-induced antigen retrieval
was carried out by steaming unstained sections in the
target retrieval solution (pH 6.1; Dako) for 30 minutes.
Serial sections were then incubated with 10 % normal
goat serum in PBS for 60 minutes to block nonspecific
binding, followed by incubation with a polyclonal anti-
Tβ4 antibody (Bachem-Peninsula Laboratories, San Carlos,
CA, USA) and with a monoclonal anti-Tβ10 antibody
(Bachem-Peninsula Laboratories), diluted 1:600 and 1:500,
respectively, in the blocking solution. Slides were then
extensively washed with PBS containing 0.01 % Triton
X-100 and incubated with a secondary reagent (EnVision
kit; Dako) according to the manufacturer’s instructions.
Diaminobenzidine was used as a chromogen. After
additional washes, color was developed using the AEC
reagent (Dako), and sections were counterstained with
Mayer’s hematoxylin and mounted. Sections of reactive
lymph nodes with Tβ4- and Tβ10-immunoreactive his-
tiocytes were used as a positive control. As a negative
control, the same procedure was applied with minor
salivary gland sections, omitting the primary antibody.
Statistical analyses
Statistical analysis was performed with SPSS version 13.0
software (SPSS, Chicago, IL, USA). Categorical and quan-
titative variables were described as numbers and percent-
ages, respectively, as well as the mean ± SD. In the eight
different patient subgroups considered, the analysis was
performed by considering the differences either in the
frequency of every single protein or in its levels. The
Mann-Whitney U test and Wilcoxon’s matched-pairs
signed-rank test were used to compare continuous
variables. Categorical variables were analyzed using the
chi-square test or Fisher’s exact test, depending on
sample size restrictions. A p value ≤0.05 was considered
significant.
Results
Proteomic analysis of salivary Tβ4 and Tβ10
Tβ4 was detected in the saliva of the vast majority of
patients affected by SICCA (pSS + ss), with percentages
ranging from 85.7 % in the subjects with ss/SSc and
those with ss/RA to 88.9 % in subjects affected by pSS
and to 100 % in patients with ss/SLE. Tβ4 was detected
in the saliva of 90 % of healthy subjects. Salivary Tβ4 was
detected at lower percentages in patients with autoimmune
diseases and without ss, ranging from 28.6 % in the SLE
group to 42.8 % in patients with SSc and those with RA
(Tables 2 and 3).
Tβ4 sulfoxide was found in a lower percentage of pa-
tients affected by SICCA (pSS + ss), ranging from 14.3 %
in the ss/RA and ss/SLE groups to 42.9 % in the ss/SSc
patients and up to 44.4 % in the pSS group. No healthy
subjects showed the presence of Tβ4 sulfoxide in saliva
(Tables 2 and 3).
Marked differences were observed among the different
subgroups of patients affected by SICCA (pSS + ss) re-
garding the occurrence of Tβ10 in saliva. The percentage
of salivary Tβ10 ranged from 14.3 % in the ss/SLE and
ss/RA groups to 42.8 % in the patients with ss/SSc and
up to 66.7 % in subjects affected by pSS.
No healthy subjects showed the presence of Tβ10 in
saliva. In patients affected by SSc, RA, and SLE but
without ss, both Tβ4 sulfoxide and Tβ10 were constantly
absent in saliva (Tables 2 and 3).
When quantitative analyses of the salivary levels of
thymosins were carried out, the highest levels of Tβ4,
Tβ10, and Tβ4 sulfoxide were found in patients with pSS
(3.5 ± 3.1 × 108, 0.2 ± 0.3 × 108, and 1.6 ± 3.3 × 108, respect-
ively) (Table 2). Tβ4 levels in subjects with pSS (3.5 ±
Table 2 Thymosin β levels and frequency detection in different
subgroups
Tβ4 Tβ10 Tβ4 sulfoxide
pSS 3.5 ± 3.1 (n = 8)a 0.2 ± 0.3 (n = 6) 1.6 ± 3.3 (n = 4)a
ss/SSc 0.7 ± 1.0 (n = 6)b 0.03 ± 0.05 (n = 3)a,b 0.2 ± 0.4 (n = 3)
ss/SLE 0.6 ± 0.4 (n = 7)b N/A (n = 1) N/A (n = 1)
ss/RA 1.2 ± 1.1 (n = 6) N/A (n = 1) N/A (n = 1)
SSc 0.3 ± 0.6 (n = 3)b N/A (n = 0)b N/A (n = 0)
SLE 0.1 ± 0.2 (n = 2)a,b N/A (n = 0)b N/A (n = 0)
RA 0.2 ± 0.4 (n = 3) N/A (n = 0)b N/A (n = 0)
HC 0.8 ± 0.6 (n = 9) N/A (n = 0)b N/A (n = 0)
Abbreviations: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc
Systemic sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis,
HC Healthy control subjects, N/A Not applicable to the comparison between
levels (as continuous variable) because of too few patients with detectable
thymosins in the considered group
Values are the mean ± SD protein levels in the extracted ion current area
(×108). Values in parentheses are the number of subjects in whom the protein
was identified
ap ≤ 0.05 vs HC either in levels of thymosin β and/or in its presence
bp ≤ 0.05 vs pSS either in thymosin β levels and/or in its presence
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3.1 × 108) were significantly higher than in the HC group
(0.8 ± 0.6 × 108) (p < 0.05).
All patients with SS and all patients with ss were
treated with a single oral dose of 5 mg of pilocarpine,
and their thymosin levels were evaluated before and
after treatment. No differences were found in Tβ4, Tβ10,
and Tβ4 sulfoxide levels before and after the drug intake
in patients with SICCA (pSS and ss).
Histology and immunohistochemistry
The histological picture of minor salivary glands in pa-
tients affected by pSS was characterized by the presence
of an inflammatory infiltrate represented mainly by lym-
phocytes, with a focus score >1 in all cases in which hist-
ology was performed. On the contrary, no inflammatory
infiltrate was detected in minor salivary glands taken
from patients in the other groups.
At the time of immunohistochemistry, Tβ4 and Tβ10
were not detectable in the minor salivary glands of the
healthy subjects. Marked differences were detected regard-
ing the expression of Tβ4 and Tβ10 in patients affected by
pSS, whereas the latter was characterized by high immuno-
staining, appearing as cytoplasmic granular deposits in aci-
nar serous cells. On the contrary, immunoreactivity for
Tβ4 was completely absent in acinar as well as ductal cells
(Fig. 1). A similar immunohistochemical staining (IHC)
pattern was detected in patients affected by ss/RA, with
minor salivary glands being characterized by a strong,
diffuse, homogeneous reactivity for Tβ10 in ductal cells
and absence of any significant immunostaining for Tβ4.
A different IHC pattern, characterized by immunostain-
ing for both Tβ4 and Tβ10 in acinar cells, was observed
in patients with ss/SSc or ss/SLE.
Discussion
In SS, the proteomic analysis of saliva appears to be a
very useful way to assess how the autoimmune disease
affects the exocrine function of salivary glands. It is an
important tool for identifying biomarkers and posttrans-
lational modifications, as well as for identifying and
quantifying peptides, proteins, and neoantigens. A number
of proteins have been indicated as pSS biomarkers, show-
ing two- to threefold up- or downregulation at signifi-
cantly different levels compared with healthy subjects or
having an exclusive presence in SS saliva. Proteins of aci-
nar origin (i.e., α-amylase, carbonic anhydrase VI, proline-
rich proteins, prolactin-inducible protein precursor) were
reduced in patients with pSS, while inflammatory phase
proteins, protease inhibitors, and antimicrobial peptides
(i.e., lactoferrin, β2-microglobulin, immunoglobulin κ-light
chain, calgranulin B, lipocalin 1 precursor, phosphatidyl-
ethanolamine binding protein, and defensins) were in-
creased, compared with those in healthy subjects [3–6].
Recently, Tβs, which are ubiquitous peptides with inter-
esting intra- and extracellular functions, were identified
in human saliva [17, 18]. Their roles in cytoskeleton re-
arrangement, anti-inflammatory response, stimulation of
wound healing, re-epithelialization of damaged cornea,
cardiac protection, and angiogenesis [9–12] support a
possible release of Tβ in the saliva of patients with oral
mucosal damage, such as in pSS, and therefore a possible
involvement of these peptides in the pathogenesis of pSS.
Tβ4 is the most abundant Tβ, representing about
70–80 % of the total Tβ content, and it is a multifunc-
tional protein that has pleotropic activities important
in cell survival and repair. It is present in all cells ex-
cept red blood cells, as well as in all studied body fluid
(saliva, tears, blood, plasma, wound fluid) [7–10]. Be-
cause Tβ4 lacks a secretion signal, it is speculated that
its presence in body fluids is due to damaged cells. It is
localized both in the cytoplasm and in the cell nucleus.
Tβ4 has been shown to promote dermal and ocular re-
pair [19], in part because of its potent chemotactic ac-
tivity. It promotes the migration of various other cells,
including stem cells from the hair follicles, resulting in
increased hair growth [10]; tumor cells, resulting in in-
creased metastasis; and embryonic progenitor cells from
cardiac tissue, resulting in the formation of new vessels
[11–13]. Tβ4 has been detected in human whole saliva and
in tears by immunological techniques [18], and recent
studies by our group evidenced that, in the oral cavity, a
main contribution derives from crevicular fluid [17], where,
as demonstrated by Reti and coworkers [20], Tβ4 plays
an important role in suppressing the production of
interleukin-8 following stimulation by tumor necrosis
factor-α and acts on the whole saliva as an antimicrobial,
anti-inflammatory, and antiapoptotic peptide on gingival
fibroblasts. The ability of Tβ4 to block apoptosis and
downregulate inflammatory cytokines may explain its
anti-inflammatory activity. Tβ4 also increases oxidative
enzymes and protects cells and tissues from oxidative
damage. In different body fluids, the oxidation product of
Tβ4 at the methionine-6 residue, Tβ4 sulfoxide was also
detectable. Tβ4 sulfoxide is generated by monocytes in the
Table 3 Immunohistochemical and salivary detection of
thymosin β in different subgroups
Group Tβ4 IHC Tβ4 saliva Tβ4 sulfoxide saliva Tβ10 saliva Tβ10 IHC
pSS − 88.9 % 44.4 % 66.7 % +++
ss/SSc + 85.7 % 42.9 % 42.8 % +
ss/SLE + 100 % 14.3 % 14.3 % +
ss/RA − 85.7 % 14.3 % 14.3 % +++
HC − 90 % 0 % 0 % −
Abbreviations: pSS Primary Sjögren’s syndrome, ss Sicca syndrome, SSc Systemic
sclerosis, SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, HC Healthy
control subjects, IHC Immunohistochemical staining, − Negative staining,
+ Positive staining
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presence of glucocorticoids, and, like Tβ4, it seems to have
anti-inflammatory properties [25, 26].
Tβ4 frequently coexists with a second member of the
Tβ family: Tβ10 [13]. Tβ10 concentration is usually about
20 times lower than Tβ4 in normal tissues, but the Tβ10/
Tβ4 ratio seems to increase in preneoplastic and neo-
plastic tissues and in activated lymphocytes [13].
Whereas Tβ4 is a potent enhancer of angiogenesis,
Tβ10 inhibits it, and changes in the ratio of the two
peptides can exert either a positive or negative control
[10]. Tβ4 can upregulate the expression of hepatocyte
growth factor and downregulate the expression of platelet-
derived growth factor-β receptor in a model of liver fibrosis,
suggesting an antifibrotic potential of Tβ4 [36, 37].
In this study, the presence and the levels of Tβ4, Tβ4
sulfoxide, and Tβ10 were determined both in saliva by a
proteomic approach and in salivary glands by immuno-
histochemistry. This integrated approach allowed us to
compare Tβ4 and Tβ10 expression in saliva and in
salivary glands of healthy subjects, patients with pSS,
and patients with ss and other autoimmune diseases.
Tβ4 was present in the saliva of the vast majority of pa-
tients complaining of ss symptoms and in healthy con-
trol subjects, but its levels were significantly higher in
subjects affected by SS than in the other subgroups.
The high levels of Tβ4 found in the saliva of patients
with SS contrasted with the absence of reactivity for
the peptide in salivary glands observed by immunohis-
tochemistry. This finding suggests that acinar cells of sal-
ivary glands constantly exposed to inflammatory damage
of SS might release high amounts of Tβ4 in the saliva,
where it would exert a cytoprotective effect in tissue re-
pair and in the anti-inflammatory response, as previously
shown in the damaged cornea [19]. Alternatively, the in-
creased apoptosis of epithelial cells that characterize
pSS can release the peptide, with the new and regener-
ating epithelial cells not producing enough peptide to
be detected by IHC [38]. This is supported indirectly by
Fig. 1 Thymosin β4 (Tβ4) and Tβ10 immunostaining in patients with primary Sjögren’s syndrome (pSS) and sicca symptoms and other autoimmune
diseases. a Tβ10 in patients with pSS: immunoreactive granules in acinar cells. b Tβ4 in patients with pSS: No immunoreactivity is detected in acinar
and ductal cells. c Tβ10 in patients with sicca syndrome and rheumatoid arthritis (ss/RA): Strong immunostaining is observed in ductal cells. d Tβ4 in
patients with ss/RA: No reactivity is observed in either acinar or in ductal cells. e Tβ4 in patients with systemic sclerosis and sicca syndrome (ss/SSc):
Granular immunostaining is observed in acinar cells. f Tβ10 in patients with ss/SSc: Immunoreactivity is observed mainly in serous acinar cells
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the observation that Tβ10 is expressed more frequently
than Tβ4 in IHC and that in fact Tβ10 is involved in apop-
tosis mechanisms [39].
Tβ10 and Tβ4 sulfoxide were selectively detectable in
patients with SICCA (ss + pSS), as compared with none
of the patients without associated ss or the healthy con-
trol subjects. Our data suggest that these two isoforms
of Tβ could be salivary biomarkers of SICCA. The high-
est levels of Tβ4 sulfoxide and Tβ10 were found in pa-
tients with pSS. The increased levels of Tβ4 sulfoxide in
pSS saliva could mirror the higher oxidative stress status
of the oral cavity related to a characteristic inflammatory
microenvironment due to the immunological destruction
of the salivary glands typical of pSS. Indeed, the release
of an increased amount of Tβ4 sulfoxide could represent
a scavenger mechanism able to reduce the negative effects
of oxidative stress on salivary proteins and enzymes, along
with a cytoprotective effect, in both forms.
Tβ10 has a similar expression pattern of Tβ4 sulfoxide
in pSS and ss saliva, and its presence may be due to a pas-
sive release from damaged cells, such as Tβ4. The increased
amount of Tβ10 in pSS saliva could be related to the acti-
vated lymphocytes present in salivary gland infiltrates.
It has been shown that thymosins prevent scarring and
fibrosis in many animal models of human pathologies
through their potent regenerative and antifibrotic effect in
reducing inflammation and in modulating oxidative dam-
age. In this scenario, our data suggest a role of thymosins
in pSS and in patients with ss related to other auto-
immune diseases, supporting a rationale for expecting
thymosins’ therapeutic effect in clinical practice in patients
with ss symptoms, as well as what has already been re-
ported in lung damage [40, 41], eye injury [19], and wound
healing of the palatal mucosa [42].
Conclusions
Proteomic analysis of the expression of Tβ4, Tβ4 sulfoxide,
and Tβ10 mirrors the different oral microenvironment of
patients with pSS and with autoimmune diseases who
complain of ss. Thymosins may potentially be used as bio-
markers in patients with pSS and patients with ss, and
IHC analysis helped us to hypothesize their possible role.
Functional studies at the epithelial cell level are necessary
to further elucidate their role.
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